| Vaccine | Doses / Schedule | Notes |
|---|---|---|
| Hepatitis B (HepB) | 3-dose: birth, 1–2 mo, 6–18 mo | 1st dose within 24 hrs of birth |
| DTaP | 5-dose: 2, 4, 6, 15–18 mo, 4–6 yr | Diphtheria, tetanus, pertussis |
| IPV (Polio) | 4-dose: 2, 4, 6–18 mo, 4–6 yr | Final dose at age 4 or older |
| Hib | 3–4 doses: 2, 4, (6 mo), 12–15 mo | Haemophilus influenzae type b |
| PCV15 or PCV20 | 4-dose: 2, 4, 6, 12–15 mo | Pneumococcal conjugate |
| RV | 2–3 doses: 2, 4, (6 mo) | Rotavirus; oral; series by 8 mo |
| MMR | 2-dose: 12–15 mo, 4–6 yr | Measles, mumps, rubella. Live vaccine. |
| Varicella (VAR) | 2-dose: 12–15 mo, 4–6 yr | Live vaccine; avoid in immunocompromised |
| Hepatitis A (HepA) | 2-dose: 12–23 mo | Separated by 6–18 months |
| Influenza | Annually starting at 6 months | 2 doses first year if naive (< 9 yr old) |
| COVID-19 | Per current CDC schedule | Updated annually |
| Vaccine | Timing | Notes |
|---|---|---|
| Tdap | 11–12 yr (then Td/Tdap every 10 yr) | Booster for DTaP; include in every pregnancy |
| HPV | 2-dose: 11–12 yr (if started before 15); 3-dose if 15+ | Up to age 26 routinely; shared decision 27–45 yr |
| MenACWY | 11–12 yr, booster at 16 yr | Meningococcal; required for college |
| MenB | 16–23 yr (preferred 16–18) | Shared decision; 2-dose series |
| Influenza | Annually | IIV or LAIV (healthy non-pregnant) |
| COVID-19 | Per current schedule | Updated annually |
| Vaccine | Recommendation | Key Notes |
|---|---|---|
| Influenza | All adults annually | High-dose or adjuvanted preferred for ≥ 65 yr |
| COVID-19 | All adults; updated annually | Follow current CDC formulation |
| Tdap/Td | Tdap x1, then Td every 10 yr | Tdap in every pregnancy (27–36 wk) |
| RSV | Adults ≥ 60 yr (shared decision); pregnancy 32–36 wk | Single dose; Abrysvo or mResvia |
| PCV15/PCV20 | All adults ≥ 65 yr; some high-risk younger adults | If PCV15: follow with PPSV23 |
| RZV (Shingrix) | All adults ≥ 50 yr; 2-dose series 2–6 mo apart | Preferred over ZVL; immunocompromised ≥ 19 yr |
| HepB | All adults < 60 yr unvaccinated; 60+ shared decision | 3-dose or 2-dose Heplisav-B |
| HepA | Unvaccinated adults at risk | Travel, liver disease, IVDU, MSM |
| MMR | Adults born after 1957 without evidence of immunity | 1–2 doses; live vaccine — avoid in pregnancy/immunocompromised |
| Varicella | 2 doses if no prior disease or vaccination | Live vaccine; avoid in pregnancy |
| MenACWY | High-risk groups, asplenia, travel | Booster every 5 yr if ongoing risk |
| HPV | Through age 26 routinely; 27–45 shared decision | Up to 3 doses if ≥ 15 yr at series start |